MedDataX Logo

SPECT/CT in Endocrine and Neuroendocrine Tumors

NCT ID: NCT00230139

Last Updated: 2008-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-01-31

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endocrine and Neuroendocrine Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPECT/CT

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors.
* Patient signed informed consent

Exclusion Criteria

* The study will not be performed in pregnant or lactating women.
* Patient will not be able or willing to tolerate the scan until its completion.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rambam Health Care Campus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rambam Health Care Campus

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zohar Keidar, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Rambam Health Care Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rambam Medical Center

Haifa, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

endocrineCTIL

Identifier Type: -

Identifier Source: org_study_id